October 8, 2015
Sanofi and Genzyme:positive investigational data from the extension study of Lemtrada
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS).